Dyax Corp.'s KALBITOR(R) (ecallantide) Data Presented at American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting

Published: Mar 02, 2010

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Data demonstrating the effectiveness of KALBITOR (ecallantide) to treat hereditary angioedema (HAE) acute attacks by primary attack location were provided in an oral presentation yesterday at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2010 Annual Meeting in New Orleans. KALBITOR, discovered and developed by Dyax Corp. (NASDAQ:DYAX), was approved by the U.S. Food and Drug Administration (FDA) late last year and is indicated for the treatment of acute attacks of HAE in patients 16 years of age or older.

Back to news